SAB BIOTHERAPEUTICS, INC. Derivative Liability, Noncurrent
SAB BIOTHERAPEUTICS, INC. (SABS) had Derivative Liability, Noncurrent of $7.23 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-08-06
- 2026-06-30: Derivative Liability, Noncurrent $7.23M.
- 2026-03-31: Derivative Liability, Noncurrent $6.12M.
- 2025-12-31: Derivative Liability, Noncurrent $5.63M; Derivative Liability, Noncurrent as first filed $5.64M.
- 2025-09-30: Derivative Liability, Noncurrent $2.38M.
| Period end | Derivative Liability, Noncurrent | Derivative Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $7.23M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $6.12M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $5.63M 10-Q · filed 2026-08-06 | $5.64M 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.38M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $1.98M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.35M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $6.39M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $4.08M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $4.09M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $6.31M 10-Q · filed 2024-05-20 | |
| 2023-12-31 | $11.77M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $417.10K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $595.86K 10-Q · filed 2023-08-21 | |
| 2023-03-31 | $238.34K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $320.93K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $357.52K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.14M 10-K · filed 2023-04-14 | |
| 2022-03-31 | $2.87M 10-K · filed 2023-04-14 | |
| 2021-12-31 | $10.72M 10-K/A · filed 2023-04-28 | |
| 2021-09-30 | $5.53M 10-Q · filed 2021-11-22 | |
| 2021-06-30 | $5.53M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $3.58M 10-Q · filed 2021-05-21 | |
| 2021-01-14 | $7.03M 10-Q · filed 2021-08-09 | |
| 2020-12-31 | $0.00 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |